Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750512 | 0.99 | FFAR1 (0.45) | FFAR1TRPV1HSD17B10MAPTMEN1 | |
| SCHEMBL1752652 | 0.92 | FFAR1 (0.45) | FFAR1TRPV1ALDH1A1L3MBTL1EPHX2 | |
| SCHEMBL1752663 | 0.92 | FFAR1 (0.44) | FFAR1TRPV1HSD17B10MAPTMEN1 | |
| SCHEMBL1751602 | 0.85 | FFAR1 (0.51) | FFAR1TRPV1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1750510 | 0.81 | FFAR1 (0.45) | FFAR1 | |
| SCHEMBL2217988 | 0.78 | FFAR1 (0.43) | FFAR1TRPV1ALDH1A1HDAC3HDAC1 | |
| SCHEMBL5167756 | 0.77 | FFAR1 (0.55) | FFAR1MAPTALDH1A1NPSR1 | |
| SCHEMBL5397270 | 0.77 | FFAR1 (0.51) | FFAR1KMT2AALDH1A1HDAC3HDAC1 | |
| SCHEMBL5390720 | 0.77 | FFAR1 (0.51) | FFAR1KMT2AALDH1A1HDAC3HDAC1 | |
| SCHEMBL1750802 | 0.75 | FFAR1 (0.48) | FFAR1TRPV1MAPTALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022079-B2 | Methods of modulating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-09-20 | — | — | US | disclosed |
| EP-1638964-B1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-7968560-B2 | Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-22 | — | — | US | disclosed |
| US-7625914-B2 | Compounds that modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-07-06 | — | — | US | disclosed |
| EP-1638964-A1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113331-A1 | NOVEL COMPOUNDS THAT MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | PPARG, PPARA, PPARD | FFAR1 5/4885TRPV1 221/4885HSD17B10 348/4885 |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | FFAR1 4/4885TRPV1 88/4885HSD17B10 312/4885 |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | PPARG, PPARD, PPARA | FFAR1 4/4885TRPV1 89/4885HSD17B10 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.